Usefulness of probucol in treating primary hypercholesterolemia.
Usefulness of probucol in treating primary hypercholesterolemia.
复制标题
普罗布考在治疗原发性高胆固醇血症中的用途。
DOI：
--
复制
发表时间：
1980
影响因子：
14.6
通讯作者：
J. Davignon
中科院分区：
文献类型：
--
作者：
M. Enjalbert;S. Lussier‐Cacan;S. Dubreuil;J. LeLorier;J. Davignon
在一项双盲交叉试验中，16例家族性高胆固醇血症患者接受了普罗布考（每天1 g）给药，这些患者先前曾接受过氯贝特的反应测试。普罗布考导致12名氯贝酸耐药患者中的5名血浆胆固醇浓度下降15%或更多（平均20.2%），另外3名患者的血浆胆固醇浓度下降8%至15%。在这12例患者中的7例以及对氯贝丁酯敏感的4例患者中的3例中，降低具有统计学显著性。因此，普罗布考在氯贝特无效的原发性高胆固醇血症患者的治疗中占有一席之地。
Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate. Probucol led to a fall in the plasma cholesterol concentration of 15% or more (mean 20.2%) in 5 of the 12 clofibrate-resistant patients and between 8% and 15% in 3 others. The reduction was statistically significant in 7 of these 12 patients as well as in 3 of the 4 patients sensitive to clofibrate. Thus, probucol has a place in the treatment of patients with primary hypercholesterolemia who do not respond to clofibrate.